-
公开(公告)号：US20230140635A1
公开(公告)日：2023-05-04
申请号：US17911022
申请日：2021-03-12
IPC分类号： C07D209/32
摘要： A compound of Formula I, which possesses 5-HT2A and/or 5-HT2C selective receptor activity, but lacks at lease some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
-
公开(公告)号：US20230138927A1
公开(公告)日：2023-05-04
申请号：US17960904
申请日：2022-10-06
IPC分类号： C12Q1/6883
摘要： This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a subject having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. This invention also relates to compositions and methods for treating subjects having or suspected of having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. In embodiments, there is a risk of an inappropriate or detrimental pro-inflammatory response, such as in a subject with a COVID-19 infection. The methods and composition provided herein can be used to determine severity and risk of complications in a subject. The methods and composition provided herein can also be used to assess the effectiveness of a therapy in a subject, such as a COVID-19 subject.
-
公开(公告)号：US11571462B2
公开(公告)日：2023-02-07
申请号：US16943828
申请日：2020-07-30
摘要： The present invention provides a CCL20 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of psoriasis and psoriatic arthritis.
-
公开(公告)号：US11540740B2
公开(公告)日：2023-01-03
申请号：US15312844
申请日：2015-05-20
发明人： Andrew S. Nencka , Andrzej Jesmanowicz , James S. Hyde , Eric S. Paulson , Lutfi Tugan Muftuler , Daniel Shefchik
IPC分类号： B33Y50/00 , G01R33/387 , G01R33/565 , B29C64/386 , B33Y50/02 , B33Y10/00 , G05B19/4099 , A61B5/055 , G01R33/24 , A61B5/05
摘要： Systems and methods for designing and fabricating three-dimensional objects with precisely computed material compositions for use in enhancing electromagnetic fields for magnetic resonance imaging (“MRI”) are provided. As examples, the fabricated object can be designed to reduce magnetic field inhomogeneities in the main magnetic field of an MRI system, or to reduce inhomogeneities in a transmit radio frequency (“RF”) field (i.e., a B1 field). As examples, the object can be a shim; a housing or other part of an RF coil; a medical device, such as a surgical implant; or component used in a medical device, such as a housing for an implantable medical device.
-
公开(公告)号：US20220356522A1
公开(公告)日：2022-11-10
申请号：US17493230
申请日：2021-10-04
IPC分类号： C12Q1/6881 , C12Q1/686
摘要： This invention relates to methods and compositions for assessing an amount of donor-specific fraction of cell-free DNA, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant organ injury (e.g., cellular injury), cellular rejection grade, antibody-mediated rejection, cardiac allograft vasculopathy, and/or cardiac arrest in a transplant subject.
-
公开(公告)号：US11491239B2
公开(公告)日：2022-11-08
申请号：US16772590
申请日：2018-12-17
摘要： Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
-
公开(公告)号：US20220288308A1
公开(公告)日：2022-09-15
申请号：US17690672
申请日：2022-03-09
发明人： Harvey J. Woehlck
摘要： An infusion pump system is operable to deliver blood to a patient from a first fluid reservoir via a first pump while mixing in a calcium-containing solution from a second fluid reservoir via a second pump. The controller precisely controls the amount of calcium-containing solution that is administered to the patient to be mixed with the blood infusate in the patient's bloodstream according to a preset blood-calcium ratio, thereby preventing citrate intoxication during large blood transfusions.
-
公开(公告)号：US20220257352A1
公开(公告)日：2022-08-18
申请号：US17673103
申请日：2022-02-16
IPC分类号： A61C9/00
摘要： A dentoalveolar stabilizer includes a tray or channel having arranged thereon a stabilizing medium, which in some instances may be a wax-like medium. The tray and/or channel is sized and shaped to be placed over the entire mandibular (i.e., lower) or maxillary (i.e., upper) dentition. The stabilizing medium holds an affected tooth (e.g., a tooth that is loose or fractured following dentoalveolar trauma) in place and uses the stability of the adjacent healthy teeth and hard tissues to help stabilize the affected tooth. The dentoalveolar stabilizer can also stabilize an alveolar fracture, a palatal fracture, and/or a non-displaced mandible fracture. The dentoalveolar stabilizer can then be kept in place until the patient can be seen and definitively managed by a dental specialist.
-
公开(公告)号：US20220251100A1
公开(公告)日：2022-08-11
申请号：US17729918
申请日：2022-04-26
发明人： John D. Imig , John R. Falck , Abdul Hye Khan , Adeniyi Adebesin
IPC分类号： C07D487/04 , A61P13/12 , C07D519/00
摘要： Described here are EET analogs conjugated to folate receptor ligands such as folic acid or folic acid analogs recognized by and selectively bound by folate receptors and other folate binding proteins and the use of such conjugated EET analogs for targeted delivery of therapeutic agents to folate-receptor bearing cell populations. More particularly, provided herein are EET analogs conjugated to folate receptor ligands and uses of such conjugated EET analogs as kidney targeted therapeutics.
-
公开(公告)号：US11369662B2
公开(公告)日：2022-06-28
申请号：US16745809
申请日：2020-01-17
摘要： The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
-
-
-
-
-
-
-
-
-
搜索结果
178 条记录 (耗时 0.038 秒)